CYTEK BIOSCIENCES INC (CTKB) Fundamental Analysis & Valuation

NASDAQ:CTKB • US23285D1090

Current stock price

4.485 USD
-0.02 (-0.55%)
Last:

This CTKB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CTKB Profitability Analysis

1.1 Basic Checks

  • In the past year CTKB has reported negative net income.
  • In the past year CTKB has reported a negative cash flow from operations.
  • In the past 5 years CTKB reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: CTKB reported negative operating cash flow in multiple years.
CTKB Yearly Net Income VS EBIT VS OCF VS FCFCTKB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M

1.2 Ratios

  • The Return On Assets of CTKB (-14.42%) is comparable to the rest of the industry.
  • With a Return On Equity value of -19.47%, CTKB perfoms like the industry average, outperforming 49.12% of the companies in the same industry.
Industry RankSector Rank
ROA -14.42%
ROE -19.47%
ROIC N/A
ROA(3y)-6.03%
ROA(5y)-3.52%
ROE(3y)-8.03%
ROE(5y)-4.69%
ROIC(3y)N/A
ROIC(5y)N/A
CTKB Yearly ROA, ROE, ROICCTKB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30 -40 -50

1.3 Margins

  • CTKB's Gross Margin of 51.84% is in line compared to the rest of the industry. CTKB outperforms 59.65% of its industry peers.
  • CTKB's Gross Margin has been stable in the last couple of years.
  • CTKB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.84%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.58%
GM growth 5Y-1.43%
CTKB Yearly Profit, Operating, Gross MarginsCTKB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CTKB Health Analysis

2.1 Basic Checks

  • CTKB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CTKB has less shares outstanding
  • Compared to 5 years ago, CTKB has less shares outstanding
  • The debt/assets ratio for CTKB is higher compared to a year ago.
CTKB Yearly Shares OutstandingCTKB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CTKB Yearly Total Debt VS Total AssetsCTKB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • CTKB has an Altman-Z score of 3.56. This indicates that CTKB is financially healthy and has little risk of bankruptcy at the moment.
  • CTKB has a Altman-Z score of 3.56. This is in the better half of the industry: CTKB outperforms 75.44% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that CTKB is not too dependend on debt financing.
  • CTKB's Debt to Equity ratio of 0.00 is fine compared to the rest of the industry. CTKB outperforms 73.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.56
ROIC/WACCN/A
WACC10.85%
CTKB Yearly LT Debt VS Equity VS FCFCTKB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • CTKB has a Current Ratio of 5.04. This indicates that CTKB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 5.04, CTKB is in the better half of the industry, outperforming 77.19% of the companies in the same industry.
  • CTKB has a Quick Ratio of 4.42. This indicates that CTKB is financially healthy and has no problem in meeting its short term obligations.
  • CTKB has a Quick ratio of 4.42. This is amongst the best in the industry. CTKB outperforms 80.70% of its industry peers.
Industry RankSector Rank
Current Ratio 5.04
Quick Ratio 4.42
CTKB Yearly Current Assets VS Current LiabilitesCTKB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CTKB Growth Analysis

3.1 Past

  • CTKB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -320.00%.
  • CTKB shows a small growth in Revenue. In the last year, the Revenue has grown by 0.52%.
  • The Revenue has been growing by 16.77% on average over the past years. This is quite good.
EPS 1Y (TTM)-320%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-157.14%
Revenue 1Y (TTM)0.52%
Revenue growth 3Y7.1%
Revenue growth 5Y16.77%
Sales Q2Q%8.12%

3.2 Future

  • Based on estimates for the next years, CTKB will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.33% on average per year.
  • Based on estimates for the next years, CTKB will show a small growth in Revenue. The Revenue will grow by 7.46% on average per year.
EPS Next Y-18.19%
EPS Next 2Y1.42%
EPS Next 3Y8.33%
EPS Next 5YN/A
Revenue Next Year5.4%
Revenue Next 2Y6.64%
Revenue Next 3Y7.24%
Revenue Next 5Y7.46%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CTKB Yearly Revenue VS EstimatesCTKB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
CTKB Yearly EPS VS EstimatesCTKB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 0.1 -0.1 -0.2

More info and screens

Find the best growth stocksShow best growing peers

0

4. CTKB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CTKB. In the last year negative earnings were reported.
  • Also next year CTKB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTKB Price Earnings VS Forward Price EarningsCTKB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTKB Per share dataCTKB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.42%
EPS Next 3Y8.33%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CTKB Dividend Analysis

5.1 Amount

  • No dividends for CTKB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CTKB Fundamentals: All Metrics, Ratios and Statistics

CYTEK BIOSCIENCES INC

NASDAQ:CTKB (3/20/2026, 2:28:05 PM)

4.485

-0.02 (-0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners64.54%
Inst Owner Change1.26%
Ins Owners9.22%
Ins Owner Change-8.63%
Market Cap576.55M
Revenue(TTM)201.49M
Net Income(TTM)-66.54M
Analysts78.18
Price Target6.29 (40.25%)
Short Float %6.25%
Short Ratio8.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.39%
Min EPS beat(2)-96.08%
Max EPS beat(2)25.3%
EPS beat(4)2
Avg EPS beat(4)-30.72%
Min EPS beat(4)-96.08%
Max EPS beat(4)43.98%
EPS beat(8)4
Avg EPS beat(8)-13.69%
EPS beat(12)5
Avg EPS beat(12)58.13%
EPS beat(16)9
Avg EPS beat(16)74.51%
Revenue beat(2)1
Avg Revenue beat(2)3.05%
Min Revenue beat(2)-0.43%
Max Revenue beat(2)6.53%
Revenue beat(4)1
Avg Revenue beat(4)-0.54%
Min Revenue beat(4)-4.73%
Max Revenue beat(4)6.53%
Revenue beat(8)2
Avg Revenue beat(8)-1.81%
Revenue beat(12)4
Avg Revenue beat(12)-3.76%
Revenue beat(16)5
Avg Revenue beat(16)-3.37%
PT rev (1m)0%
PT rev (3m)7.25%
EPS NQ rev (1m)25%
EPS NQ rev (3m)20%
EPS NY rev (1m)-18.7%
EPS NY rev (3m)-13.18%
Revenue NQ rev (1m)-1.01%
Revenue NQ rev (3m)-0.45%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)0.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.86
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB 1.87
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS1.57
BVpS2.66
TBVpS2.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.42%
ROE -19.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.84%
FCFM N/A
ROA(3y)-6.03%
ROA(5y)-3.52%
ROE(3y)-8.03%
ROE(5y)-4.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.58%
GM growth 5Y-1.43%
F-Score4
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.28%
Cap/Sales 2.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.04
Quick Ratio 4.42
Altman-Z 3.56
F-Score4
WACC10.85%
ROIC/WACCN/A
Cap/Depr(3y)62.27%
Cap/Depr(5y)186.96%
Cap/Sales(3y)2.15%
Cap/Sales(5y)3.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-320%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-157.14%
EPS Next Y-18.19%
EPS Next 2Y1.42%
EPS Next 3Y8.33%
EPS Next 5YN/A
Revenue 1Y (TTM)0.52%
Revenue growth 3Y7.1%
Revenue growth 5Y16.77%
Sales Q2Q%8.12%
Revenue Next Year5.4%
Revenue Next 2Y6.64%
Revenue Next 3Y7.24%
Revenue Next 5Y7.46%
EBIT growth 1Y-96.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year107.77%
EBIT Next 3Y34.41%
EBIT Next 5YN/A
FCF growth 1Y-141%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-118.46%
OCF growth 3YN/A
OCF growth 5YN/A

CYTEK BIOSCIENCES INC / CTKB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CYTEK BIOSCIENCES INC (CTKB) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CTKB.


What is the valuation status for CTKB stock?

ChartMill assigns a valuation rating of 0 / 10 to CYTEK BIOSCIENCES INC (CTKB). This can be considered as Overvalued.


How profitable is CYTEK BIOSCIENCES INC (CTKB) stock?

CYTEK BIOSCIENCES INC (CTKB) has a profitability rating of 1 / 10.


How financially healthy is CYTEK BIOSCIENCES INC?

The financial health rating of CYTEK BIOSCIENCES INC (CTKB) is 6 / 10.